The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16389 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Jing Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Hydroxychloroquine, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Aims
Research on hydroxychloroquine (HCQ) for children with chronic immune thrombocytopenia (ITP) is limited. The association between antinuclear antibody (ANA) positivity and its efficacy remains unclear.
Methods
This retrospective cohort study compared the clinical characteristics of children with chronic ITP who received HCQ with those who did not, as well as patients who responded to HCQ at 3 months with those who did not. Mixed‐effects models were performed to assess the effect of HCQ on platelet counts and the association between ANA and its efficacy. Records of HCQ‐related side effects were reviewed.
Results
A total of 191 children with chronic ITP were included in this study, including 42 patients who received HCQ. At the last follow‐up, 69.0% of patients treated with HCQ achieved complete response or response, with a median follow‐up time of 56 months (range: 17–146 months), a higher frequency compared to 48.3% of patients who were not treated with HCQ (odds ratio [OR], 2.39; 95% confidence interval [CI], 1.15–4.95). The overall response rates to HCQ were 56.8% (21/37) at 3 months and 40.5% (15/37) at 1 year. HCQ was effective for increasing platelet counts (mean difference: 23.82 × 10 9 /L; 95% CI: 7.44–40.21), but the association between ANA positivity and its efficacy was not found. Side effects were recorded in six patients (14.3%).
Conclusions
HCQ was associated with increased platelet counts in chronic ITP children. The baseline ANA level was not found to be associated with the efficacy of HCQ. Side effects of HCQ warrant consideration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Medical Oncology, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Institute of Clinical Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Jing Liu
Förderung
- National High Level Hospital Clinical Research Funding of China
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Liu, J., Zhang, Y., Song, H., Ma, M., Li, Z., Zhang, L., Song, Y., Lyu, Z., Lu, Y., & Xiao, J. (2025). The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16389
Vancouver
Liu J, Zhang Y, Song H, Ma M, Li Z, Zhang L, et al. The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16389
BibTeX
@article{Liu2025,
author = {Liu, Jing and Zhang, Yuelun and Song, Hongmei and Ma, Mingsheng and Li, Zhuo and Zhang, Lejia and Song, Yuqing and Lyu, Zichao and Lu, Yixiu and Xiao, Juan},
title = {The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16389}
}
EUVIMED